PROTECT VIII kids extension study: Long‐term safety and efficacy of BAY 94‐9027 (damoctocog alfa pegol) in children with severe haemophilia A

INTRODUCTION: BAY 94‐9027 (damoctocog alfa pegol; an extended half‐life PEGylated recombinant factor VIII [FVIII]) demonstrated efficacy and safety in previously treated paediatric patients (PTPs) aged <12 years with severe haemophilia A in the PROTECT VIII Kids study (NCT01775618). AIM: To evalu...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Haemophilia
Autors principals: Mancuso, Maria Elisa, Biss, Tina, Fischer, Kathelijn, Maas Enriquez, Monika, Steele, MacGregor, Wang, Maria, Tseneklidou‐Stoeter, Despina, Ahuja, Sanjay, Kenet, Gili
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2021
Matèries:
Original Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8251516/
https://ncbi.nlm.nih.gov/pubmed/33724632
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/hae.14294
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars